Diabetes is an enormous and ever-growing calamity and a global public health threat of the 21st century. Besides
insulin and oral hypoglycaemic drugs, blockage of the renin-angiotensin system (RAS) denotes a key
pharmacotherapy for the management of cardiovascular (CVD) and
chronic kidney diseases (CKD), which are the leading causes of disability and death among diabetic patients.
Neprilysin (NEP) inhibition, auxiliary to RAS blockage increases the bioavailability of
natriuretic peptides and benefits the cardio-renal system.
Omapatrilat, a dual
angiotensin-converting enzyme (ACE) and NEP inhibitor has been reported to show superior
anti-hypertensive, anti-atherosclerotic,
insulin-sensitizing, cardiovascular and renoprotective effects to
ACE inhibitors in experimental animal models for diabetes. In clinical trials on hypertensive subjects
Omapatrilat increased the risk of
angioedema due to which its further development as
anti-hypertensive drug was hampered. This event prompted the development of
angiotensin receptor neprilysin inhibitors (ARNi). The first representative of ARNi,
LCZ696 (
Sacubitril/ Valsartan) halted cardiovascular and renal functional decline and hence protected against CKD and CVD. Recently,
LCZ696 was approved by U.S. Food and Drug Administration for the treatment of
heart failure. This concise review intends to summarise the currently available reports on NEPi as a therapeutic intervention to treat CVD and CKD associated with diabetes.